SLC5A2 and heart failure: Evolving role of SGLT2 inhibitors: SGLT2 inhibitors have been demonstrated to reduce the incidence of cardiovascular death and heart failure in patients with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) [37].